Navigation Links
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Date:4/26/2008

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (entecavir) resulted in greater long-term viral load reduction than adefovir at 96 weeks -- consistent with earlier 12-week results (primary endpoint). Suppression of viral load to undetectable levels is a measure of antiviral treatment response and is an important goal of chronic hepatitis B treatment. These data were presented today in Milan, Italy, at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL).

The E.A.R.L.Y. study is an open-label, randomized, viral kinetics study of 69 antiviral-naive chronic hepatitis B e-antigen (HBeAg) positive patients, comparing the antiviral activity of BARACLUDE and adefovir. All patients in this study had a high viral load at study entry.(1) Of the 49 patients who remained in the study at 96 weeks, 79 percent (n=23/29) of BARACLUDE-treated patients and 50 percent (n=10/20) of adefovir-treated patients achieved undetectable viral load.(2) The mean reduction in viral load from baseline in patients treated with BARACLUDE was -7.82 log(10) copies/mL and was -5.96 log(10) copies/mL in patients treated with adefovir at week 96.

"BARACLUDE maintains considerable antiviral efficacy through two years of treatment in this analysis," said Nancy Leung, M.D., of the Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China. "This is important information for health care providers to consider when evaluating initial treatment options to suppress viral load in antiviral-naive chronic hepatitis B patients."

The safety profile
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
2. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
3. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
9. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Many Heart Attack Patients Dont Get Best Emergency Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2008)...- Southern Research Institute,today announced that...ted,the organization to participate in the newly-f...Network (MLPCN). The MLPCN -- a collaborative,rese... Program which is,designed to benefit human health... and validate future targets for drug discovery., ...
(Date:9/4/2008)...umab to be Presented, PRINCETON, N.J., Sept. 4 /P...DX ) announced today that nine clinical abstracts ...ibody, in melanoma are scheduled to be,the subject...pean Society,for Medical Oncology (ESMO) being hel...following abstracts will include updated one-year ...
(Date:9/4/2008)...h Two Abstracts Accepted for Presentation, and...IDGEWATER, N.J., Sept. 4 /- Aegerion ...company focused on the treatment of,cardiovascular...tment of,Peter L. Garrambone, Jr. to the Company,s...ncludes more than 50 pharmaceutical,transactions e...
(Date:9/3/2008)...tCall/ -- Simcere,Pharmaceutical Group (NYSE: SCR... generic pharmaceuticals and manufacturer of the p...wn as Endostar) in China,announced the interim re...quest of the SFDA, Simcere initiated a Phase IV cl...erapeutic efficacy of Endu, a modified,version of ...
Breaking Medicine Technology:Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 2Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 3Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network 4Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 2Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 2Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study 3Workshop Helps Parents Kids Talk About Sex 23817 1Workshop Helps Parents Kids Talk About Sex 23817 2Non parental care of infants tied to unfavorable feeding practices 23813 1Non parental care of infants tied to unfavorable feeding practices 23813 2Non parental care of infants tied to unfavorable feeding practices 23813 3I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 1I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 2I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 3I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 4I Play Clean 28TM 29 and Old Spice Kick Off Campaign Challenging High School Students to Pledge Against Steroid Use 23809 5Chindex International Inc Announces CDC Contract Signing 23805 1Chindex International Inc Announces CDC Contract Signing 23805 2Chindex International Inc Announces CDC Contract Signing 23805 3Chindex International Inc Announces CDC Contract Signing 23805 4
...ter damage caused by,flooding over the weekend, FD...pcoming Antiviral Drugs Advisory Committee,meeting... for,maraviroc 300 milligram tablets. Originally s...aluation and Research Advisory Committee,Conferenc... the,meeting has been relocated to , Crown Plaza H...
...-- Sirion Therapeutics,Inc., an ophthalmic-focuse...it has received orphan drug designation from the F...al therapy,ganciclovir, for the treatment of acut...keted by Laboratoires Thea in Europe under,the bra...o,Virgan(R) for the United States from Laboratoire...
Other Medicine Technology:FDA Announces Change of Location Notice for Upcoming Advisory,Committee Meeting 2Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic,Drug to Treat Viral Eye Infection 2
(Date:9/5/2008)...G, Pa., Sept. 5 /PRNewswire-USNewswire/ -- Childre...r access to comprehensive,services to protect thei...n,in grants that were announced today by the Depar...vices for children and families, the department,be...ren,s Services Planning,initiative, ICSP, in 2004....
(Date:9/5/2008)..., Md., Sept. 5 /PRNewswire-USNewswire/ -- The Heal...day announced $39 million in grants to,increase an...centers., "These grants continue President Bush,s...whose services now reach more economically,vulnera...r before," HRSA,Administrator Elizabeth M. Duke sa...
(Date:9/5/2008)...ontrolled, but you need to know what triggers them...thDay News) -- If you are one of the 36 million Am...is nowhere in the United States that is free from ... shows. , Allergies don,t only happen in the sp...ell. In the fall, the most challenging cities to l...
(Date:9/5/2008)...N, Sept. 5 /PRNewswire-USNewswire/ -- Speaker Nanc...upport of the aims of the "Stand,Up to Cancer" tel...re is not a person in our country who has not seen...s 565,000 Americans annually, and each,year there ... must work,together to make eradicating the scourg...
Breaking Medicine News(10 mins):Health News:Pennsylvania Counties Receive Grants to Improve Services for Children 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:No Place Safe From Allergies 2
...ents undergoing chemotherapy and radiation therapy...he study is also trying to investigate what can be...althy diet during treatment. Researchers at the U...cts of chemotherapy and radiation therapy on the s...
...Canada’s conjoined twins and to the public, who ha...d //after days of several tests that the twins are...nown by the names Krista and Tatiana Hogan came in...The twins, who are four months of age, portray dis...
...the quickest way to get from one floor to another....nding heart triggers anxiety or fear – possibly pr... Ellen W. Leen-Feldner, a University of Arkansas...nts who tend to respond fearfully to such common b...
...n is ninty-eight percent effective, offers a lower...rgery// for the treatment of varicoceles (varicose...n in men can cause pain, testicular atrophy or fer... life. “Varicoceles are a major, but underdiagnose...
Other Medicine News:Health News:Special Diets Necessary for Those Undergoing Chemotherapy 2Health News:Panic may Lead to Serious Mental Health Problems in Adolescents 2Health News:Nonsurgical Therapy Highly Effective for Pain and Infertility in Men 2
Features and Benefits: 1-12channel pipette This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-A
...ell plates in mind, Pipetman Ultra Multichannel is...tions: PCR* sequencing, immunology assays, series ...mond Tips from Gilson's patented Rocky Rack system...e productivity.,* PCR process is covered by US pat...
...ion, ergonomics, and value!, Comfortable feel and...andle , Finer control while pipetting with smooth,...ction with long, lever tip ejector , Completely au...ion without the need for recalibration , Easy-to-r...
Finnpipette Focus multichannel pipettes speed up repeat dispensing of reagents into microplates, with super blow-out for 0.1-10 l volumes. The improved ergonomic design of Finnpipette Focus multichan
Medicine Products: